REGENERON PHARMACEUTICALS INC
StreetZero Signal 63
About REGENERON PHARMACEUTICALS INC
Regeneron Pharmaceuticals, Inc. is a biotechnology company that discovers, develops, and commercializes medicines for serious diseases. It has pioneered antibody technologies such as VelociSuite and markets products including EYLEA, Dupixent, and Libtayo. The company maintains major collaborations with partners like Sanofi and focuses on areas including ophthalmology, immunology, and oncology.
LATEST FUNDINGRule 144
$1.6M
Announced 2026-10-30
EMPLOYEES10001+
FOUNDED1988
HQTarrytown, NY, USA
Industry
Public Equity (NASDAQ)
Tags
BiotechnologyPharmaceuticalsPublic CompanyNASDAQ
Investors
Not disclosed in the source filing. Form D filings do not list investors — StreetZero surfaces them from news where available.
Key highlights
- Publicly traded biotechnology company focused on antibody-based therapies.
- Rule 144 transaction represents share sale rather than primary capital raise.
- Maintains key commercial partnerships including with Sanofi.
- Portfolio includes blockbuster products EYLEA and Dupixent.
- Operates with proprietary VelociSuite antibody discovery platform.
Ask StreetZero about REGENERON PHARMACEUTICALS INC
Put our AI to work on this deal.
Similar companies
Other Public Equity (NASDAQ) deals, ranked by Signal.
Source document & SEC filing
The source SEC filing and the cached document are available to members only. Sign in to view and download them.
Sign in to view the filing Create free account